Unit of Regenerative Therapy, Service of Plastic, Reconstructive and Hand Surgery, Department of Musculoskeletal Medicine, Lausanne University Hospital, Lausanne, Switzerland.
Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Stem Cell Res Ther. 2020 Oct 6;11(1):432. doi: 10.1186/s13287-020-01949-4.
The autologous nerve graft, despite its donor site morbidity and unpredictable functional recovery, continues to be the gold standard in peripheral nerve repair. Rodent research studies have shown promising results with cell transplantation of human adipose-derived stem cells (hADSC) in a bioengineered conduit, as an alternative strategy for nerve regeneration. To achieve meaningful clinical translation, cell therapy must comply with biosafety. Cell extraction and expansion methods that use animal-derived products, including enzymatic adipose tissue dissociation and the use of fetal bovine serum (FBS) as a culture medium supplement, have the potential for transmission of zoonotic infectious and immunogenicity. Human-platelet-lysate (hPL) serum has been used in recent years in human cell expansion, showing reliability in clinical applications.
We investigated whether hADSC can be routinely isolated and cultured in a completely xenogeneic-free way (using hPL culture medium supplement and avoiding collagenase digestion) without altering their physiology and stem properties. Outcomes in terms of stem marker expression (CD105, CD90, CD73) and the osteocyte/adipocyte differentiation capacity were compared with classical collagenase digestion and FBS-supplemented hADSC expansion.
We found no significant differences between the two examined extraction and culture protocols in terms of cluster differentiation (CD) marker expression and stem cell plasticity, while hADSC in hPL showed a significantly higher proliferation rate when compared with the usual FBS-added medium. Considering the important key growth factors (particularly brain-derived growth factor (BDNF)) present in hPL, we investigated a possible neurogenic commitment of hADSC when cultured with hPL. Interestingly, hADSC cultured in hPL showed a statistically higher secretion of neurotrophic factors BDNF, glial cell-derived growth factor (GDNF), and nerve-derived growth factor (NFG) than FBS-cultured cells. When cocultured in the presence of primary neurons, hADSC which had been grown under hPL supplementation, showed significantly enhanced neurotrophic properties.
The hPL-supplement medium could improve cell proliferation and neurotropism while maintaining stable cell properties, showing effectiveness in clinical translation and significant potential in peripheral nerve research.
尽管自体神经移植物存在供体部位发病率和功能恢复不可预测等问题,但它仍然是周围神经修复的金标准。啮齿动物研究表明,在生物工程导管中移植人脂肪源性干细胞(hADSC)作为神经再生的替代策略具有很有前景的结果。为了实现有意义的临床转化,细胞治疗必须符合生物安全性。使用动物源性产品(包括酶消化脂肪组织和使用胎牛血清(FBS)作为培养基补充)进行细胞提取和扩增的方法,具有传播人畜共患传染病和免疫原性的潜在风险。近年来,人血小板裂解液(hPL)已被用于人类细胞扩增,在临床应用中显示出可靠性。
我们研究了是否可以常规地以完全无异种的方式(使用 hPL 培养基补充剂并避免胶原酶消化)分离和培养 hADSC,而不会改变其生理学和干细胞特性。比较了两种提取和培养方案在干细胞标志物表达(CD105、CD90、CD73)和成骨细胞/脂肪细胞分化能力方面的差异。
我们发现,在两种检查的提取和培养方案中,在簇分化(CD)标志物表达和干细胞可塑性方面没有显著差异,而在 hPL 中的 hADSC 与通常添加 FBS 的培养基相比具有更高的增殖率。考虑到 hPL 中存在的重要关键生长因子(特别是脑源性神经营养因子(BDNF)),我们研究了在 hPL 培养时 hADSC 可能的神经发生承诺。有趣的是,与 FBS 培养的细胞相比,在 hPL 中培养的 hADSC 显示出统计学上更高的神经营养因子 BDNF、胶质细胞源性生长因子(GDNF)和神经源性生长因子(NFG)的分泌。当与原代神经元共培养时,在 hPL 补充物下培养的 hADSC 显示出明显增强的神经营养特性。
hPL 补充培养基可以在保持稳定细胞特性的同时,提高细胞增殖和神经营养性,在临床转化方面具有有效性,并在周围神经研究方面具有重要的潜在应用价值。